TABLE 2.
Longitudinal analysis of demographic and clinical characteristics of the study individuals
| Patient IDa no. | Patient age (yr) | Patient sexb | Patient ethnicity | HLA class I types | Antiretroviral treatment and subsequent STIsc | Initial presentation
|
Day p.p.d of T-cell analysis in chronic infection (no. of days off therapy) | Time of analysis of chronic infection
|
Epitope studied (sequence) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD4+ T-cell count (cells/μl) | HIV-1 RNA (copies/ml) | CD4+ T-cell count (cells/μl) | HIV-1 RNA (copies/ml) | ||||||||
| AC-15 | 40 | M | Caucasian | A1,3; B7,8; Cw7 | Yes | 413 | 27,000 | 1752 (765) | 542 | 12,200 | B8-FL8 (FLKEKGGL) |
| AC-14 | 44 | M | Caucasian | A2,3; B8,62; Cw7,10 | Yes | 981 | 951,000 | 686 (186) | 969 | 10,860 | B8-FL8 (FLKEKGGL) |
| AC-46 | 49 | M | Caucasian | A1,26; B8,51; Cw7,15 | Yes | ND | 123,000 | 1040 (547) | 562 | 20,300 | B8-FL8 (FLKEKGGL) |
| AC-02 | 42 | M | Caucasian | A11,29; B8,44; Cw4 | Yes | ND | 4.85 × 106 | 941 (98) | 625 | 18,400 | B8-FL8 (FLKEKGGL) |
| AC-09 | 35 | M | Hispanic | A2,31; B61; Cw10 | Yes | 365 | 750,000 | 904 (270) | 361 | 30,277 | A2-IV9 (ILKEPVHGV) |
| AC-131 | 32 | M | Caucasian | A1,3; B8,15; Cw7 | No | 475 | 750,000 | 477 | NDe | 175,000 | B8-EI8 (EIYKRWII) |
| AC-177 | 44 | M | Caucasian | A1,2; B8; Cw7 | No | 363 | 26,800 | 162 | 217 | 427,000 | B8-EI8 (EIYKRWII) |
| AC-132 | 30 | M | Caucasian | A3,68; B14,44; Cw8,16 | No | 815 | 5.6 × 106 | 27 | 790 | 115,000 | A3-QK10 (QVPLRPMTYK) |
| AC-160 | 46 | M | Caucasian | A1,2; B7,27; Cw1,7 | No | ND | 468,000 | 205 | 874 | 2,830 | B27-KK10 (KRWIILGLNK) |
| AC-121 | 37 | M | Hispanic | A1,24; B35,57; Cw7,12 | No | 858 | 12,600 | 562 | ND | 5,940 | B57-KF11 (KAFSPEVIPMF) |
a
ID, identification.
b
M, male.
c
For details on the length of antiretroviral treatment, the length of STIs, and the evolution of HIV-1 RNA and CD4+ T-cell counts, see reference 28.
d
Day p.p., day postpresentation.
e
ND, not determined.